UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
Commission File Number:
(State or other jurisdiction of |
(I.R.S. Employer | |
incorporation or organization) | Identification No.) | |
|
| |
(Address of principal executive offices) |
(Zip Code) |
(
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name
of exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01 Regulation FD Disclosure.
On June 9, 2023, AmerisourceBergen Corporation (the “Company”) issued a press release announcing that TPG, a global alternative asset management firm (“TPG”), and the Company completed their previously announced acquisition of OneOncology, a network of oncology practices (“OneOncology”). A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such filing.
Item 8.01 Other Events.
On June 9, 2023, TPG and the Company completed their previously announced acquisition of OneOncology through a joint venture in which the Company purchased a minority equity interest.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number | Description of Exhibit | |
99.1. | News Release of AmerisourceBergen Corporation and TPG, dated June 9, 2023. | |
104 | Cover Page Interactive Data File (formatted as inline XBRL) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AMERISOURCEBERGEN CORPORATION | ||
Date: June 9, 2023 | By: | /s/ James F. Cleary |
Name: | James F. Cleary | |
Title: | Executive Vice President and Chief Financial Officer |
Exhibit 99.1
PRESS RELEASE | |
AmerisourceBergen Corporation | |
1 West First Avenue | |
Conshohocken, PA 19428 | |
TPG and AmerisourceBergen Announce Completion of Acquisition of ONEONCOLOGY
CONSHOHOCKEN, PA, SAN FRANCISCO AND FORT WORTH, TEXAS June 9, 2023 — TPG (NASDAQ: TPG), a global alternative asset management firm, and AmerisourceBergen Corporation (NYSE: ABC) today announced the completion of their previously announced acquisition of OneOncology, a network of leading oncology practices.
TPG has acquired a majority interest in OneOncology, and AmerisourceBergen has acquired a minority interest in the company. OneOncology’s affiliated practices, physicians, and management team have also retained a minority interest in the company. The partnership provides OneOncology with additional resources to grow its platform and invest behind clinical, operational, and technical capabilities to continue to deliver high-quality, comprehensive patient care.
About TPG
TPG is a leading global alternative asset management firm, founded in San Francisco in 1992, with $137 billion of assets under management and investment and operational teams around the world. TPG invests across five multi-strategy platforms: Capital, Growth, Impact, Real Estate, and Market Solutions and our unique strategy is driven by collaboration, innovation, and inclusion. Our teams combine deep product and sector experience with broad capabilities and expertise to develop differentiated insights and add value for our fund investors, portfolio companies, management teams, and communities. For more information, visit www.tpg.com or on Twitter @TPG.
About AmerisourceBergen
AmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500 with more than $200 billion in annual revenue.
Investors: | Bennett S. Murphy |
Senior Vice President, Head of Investor Relations & Treasury | |
610-727-3693 | |
bmurphy@amerisourcebergen.com |
TPG | |
Leslie Shribman and Courtney Power | |
media@tpg.com |
2
Cover |
Jun. 09, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jun. 09, 2023 |
Entity File Number | 1-6671 |
Entity Registrant Name | AmerisourceBergen Corporation |
Entity Central Index Key | 0001140859 |
Entity Tax Identification Number | 23-3079390 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 1 West First Avenue |
Entity Address, City or Town | Conshohocken |
Entity Address, State or Province | PA |
Entity Address, Postal Zip Code | 19428-1800 |
City Area Code | 610 |
Local Phone Number | 727-7000 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common stock |
Trading Symbol | ABC |
Security Exchange Name | NYSE |
Entity Emerging Growth Company | false |
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end
&ULS9Q-<]LV$(;OG>E_8-6S+$M.TMBQFW$4*Z.)$[N6 MD[2]9"!R)6$, BI 6M*_+T"*BCX(<'W)V@=;IA; OL^"()< >/YVF8KH$;3A M2EZTND?'K0ADK!(NIQ>M+Z/VY:@_'+8BDS&9,*$D7+2D:KW]\]=?(OMS_EN[ M'0TXB.0L>J_B]E!.U)OH,TOA+/H $C3+E'X3?64B=T?4@ O045^E
F0+I1_,4:Q27(6C
MC&6YV=1VO#Q>_Y3%SP67#V?NUY@9B"PO: JK:_B5(XOWM>-3JZ8TGZ;L^^LC1'BS33%-G6!#
M'*4,>^%8DCP6EHXV+^1X;/9^^F" M# <9"UVE'=W^#$C5,@=^ JQM,O+-W?W
MY$-4/^LB8$(&.L98^.^C$T'H[8%K4H$%QO 2C!,L5(]7B//KJ ?/T&GH6XJ/';ID!4:6)S.PHP1!^9C
M@/:(=>H!M<<\I13H8%R ZM/N#H0Y$;M\(KQX27BC7C( FA=KQMSV!WTSF?A&XI ]ECI)3M@LE)[^T)@<]%-C4%,*
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MTL4"5.TY%SRF6.R$
HR\US8ZXUQ>+N4*!YI\2Z;E
M